Central Nervous System Tumor, Pediatric
10
1
2
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
2 terminated out of 10 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
Genetic Study of Brain Tumors in Young Children